A year later, none of the $1.5B for rare disease has flowed to patients

Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

Health Minister Mark Holland speaks to reporters in West Block on Jan. 31. Bilateral agreements to transfer funds under the National Strategy for Drugs for Rare Diseases to increase drug access as well as diagnostic and screening capacity haven’t yet been signed, writes David Renwick.The Hill Times photograph by Andrew Meade

Opinion

BY DAVID RENWICK

February 28, 2024

It’s no secret that Canadians wait too long to access health care. Nowhere is this more evident than for Canadians living with a rare disease.

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy